Stifel Maintains Buy on DarioHealth, Lowers Price Target to $5
Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $10 to $5.
Last updated: 2026-11-14 20:25:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
DarioHealth Corp. (DRIO) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1.26, with a market capitalization of $18.48M and a P/E ratio of 0.00. Over the past 52 weeks, its price has ranged from $1.26 to $14.77. This page covers its latest market performance, valuation, price trends and company information.
$18.48M | |
$1.62 | |
$1.72 | |
$1.26 | |
$1.65 | |
73.77K | |
43.99K | |
-- | |
$14.77 | |
$1.26 | |
-- | |
-- |
DarioHealth Corp. (DRIO) last closed at $1.26 as of 2026-11-13 23:39:00, down 22.42% ($0.37) from the previous close of $1.65.
During the latest regular trading session, DRIO traded between $1.26 and $1.72, with a volume of 73.77K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, DarioHealth Corp. (DRIO) moved from $2.73 to $1.26, representing a decline of 53.76% ($1.47).
The stock traded between $1.26 and $3.02 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 75.89 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.0%
DRIO is currently trading at $1.26, placing it 0.0% of the way from its 52-week low of $1.26 to its 52-week high of $14.77. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 165 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to DarioHealth Corp. and DRIO stock.
Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $10 to $5.
DarioHealth (NASDAQ:DRIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
DarioHealth Corp. (DRIO) reported a quarterly loss of $0.44 per share, beating consensus estimates of $0.51 loss, with a 13.73% earnings surprise. Revenues reached $5.31 million, slightly exceeding expectations. However, the stock has plummeted 81.3% year-to-date compared to the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.66) by 27.69 percent. This is a 75.39 percent increase over losses of $(1.91) per share from the
Eligible investors can buy real shares of DarioHealth Corp. (DRIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DRIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DRIO shares and USD.
DRIO Shares to USD
1.00 DRIO shares = 1.26 USD
Calculations are estimates based on the latest available price and are for reference only.